News >

Expert Explains Evolution of De-Escalating Therapies in HER2+ Breast Cancer

Ellie Leick
Published: Friday, Jul 19, 2019

Keerthi Gogineni, MD, MSHP, assistant professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute

Keerthi Gogineni, MD, MSHP

Several trials, such as APT and KRISTINE, have examined the effects of de-escalating treatment for patients with HER2-positive breast cancer in an effort to decrease toxicity without comprising efficacy, explained Keerthi Gogineni, MD, MSHP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication